![Emi Yamamoto](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 144 397 $ al 31/05/2026
Emi Yamamoto currently works at Carna Biosciences, Inc., as Chief Financial Officer & Director from 2018 and CarnaBio USA, Inc., as President & Director from 2019.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
CARNA BIOSCIENCES, INC. 0,28 % | 31/12/2025 | 54.600 ( 0,28 % ) | 144 397 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CARNA BIOSCIENCES, INC. | Director Financiero/CFO | 01/10/2018 |
CarnaBio USA, Inc.
 CarnaBio USA, Inc. Medical DistributorsDistribution Services Wholesales kinases protein, substrates and biotinylates kinases products | Presidente | 01/02/2019 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 2 |
|---|---|
Carna Biosciences, Inc.
 Carna Biosciences, Inc. BiotechnologyHealth Technology Engages in the drug discovery business | Health Technology |
CarnaBio USA, Inc.
CarnaBio USA, Inc. Medical DistributorsDistribution Services Wholesales kinases protein, substrates and biotinylates kinases products | Distribution Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
